Testolactone
- Generic Name
- Testolactone
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24O3
- CAS Number
- 968-93-4
- Unique Ingredient Identifier
- 6J9BLA949Q
- Background
An antineoplastic agent that is a derivative of progesterone and used to treat advanced breast cancer.
- Indication
For palliative treatment of advanced breast cancer in postmenopausal women.
- Associated Conditions
- -
- Associated Therapies
- -
Treatment of Boys With Precocious Puberty
Phase 2
Completed
- Conditions
- Precocious Puberty
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 80
- Registration Number
- NCT00001202
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Testolactone for the Treatment of Girls With LHRH Resistant Precocious Puberty
Phase 2
Completed
- Conditions
- Polyostotic Fibrous DysplasiaPrecocious Puberty
- First Posted Date
- 1999-11-04
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- Target Recruit Count
- 100
- Registration Number
- NCT00001181
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath